Tango Therapeutics, Inc. (TNGX) Financial Analysis & Valuation | Quarter Chart
Tango Therapeutics, Inc. (TNGX)
TNGXPrice: $7.87
Fair Value: 🔒
🔒score
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine pho... more
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of... more
Description
Shares
| Market Cap | $869.37M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Barbara L. Weber |
| IPO Date | 2020-09-03 | CAGR | 0.11% |
| Employees | 155 | Website | www.tangotx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
TNGX chart loading...
Fundamentals
Technicals
| Enterprise Value | $535.32M | P/E Ratio | -8.65 |
| Forward P/E | -15.65 | PEG Ratio | — |
| P/S Ratio | 35.36 | P/B Ratio | 6.37 |
| P/CF Ratio | -5.8 | P/FCF Ratio | -5.76 |
| EPS | $-0.91 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 53.28% | Gross Margin | 0.97% |
| Operating Margin | -6.47% | Profit Margin | -5.99% |
| ROE | -0.8% | ROA | -0.61% |
| ROCE | -0.79% | Current Ratio | 4.75 |
| Quick Ratio | 4.75 | Cash Ratio | 0.99 |
| Debt/Equity | 0.26 | Interest Coverage | — |
| Altman Z Score | 0.4 | Piotroski Score | — |